Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes mRNA vaccines, cell and gene therapies, targeted antibodies, small molecule immunomodulators, Ribologicals, and next-generation immunomodulators. Our approach has created a robust and diversified product pipeline across infectious disease and oncology, including our first commercial product, COMIRNATY, our COVID-19 vaccine. COMIRNATY is the first ever approved mRNA drug product. Our clinical pipeline includes over 19 product candidates in 24 clinical trials, including five randomized Phase 2 clinical trials. We aim for multiple product launches in the next three to five years. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. We believe we are well-positioned to develop and commercialize the next generation of immunotherapies with the potential to transform treatment paradigms for many severe diseases.
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
German Chancellor Olaf Scholz to Visit BioNTech: Construction of First Proprietary Plasmid DNA Production Completed
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
Virtual Annual SVB Securities Global Healthcare Conference
Credit Suisse London Global Healthcare Conference
Cowen 43rd Annual Health Care Conference
Data Provided by Refinitiv. Minimum 15 minutes delayed.